Renal complications to COVID-19

Descripción del Articulo

Patients treated with inhibitors or blockers of the renin-angiotensin-aldosterone system (RAAS), showed no increased risk to develop COVID-19, nor an increased risk to developed a more critical stage of the disease. Patients with COVID-19, at the time of hospitalization showed a high proportion of t...

Descripción completa

Detalles Bibliográficos
Autor: Rozas-Olivera, Victor Vladimiro
Formato: artículo
Fecha de Publicación:2021
Institución:Fundación Instituto Hipólito Unanue
Repositorio:Diagnóstico
Lenguaje:español
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/235
Enlace del recurso:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/235
Nivel de acceso:acceso abierto
Materia:COVID-19
sistema renina-angiotensina-aldosterona
injuria renal aguda
renin-angiotensin-aldosterone system
acute kidney injury
id REVFIHU_e912fa1e8cf8aa02a11c5bf3c76cb338
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/235
network_acronym_str REVFIHU
network_name_str Diagnóstico
repository_id_str
spelling Renal complications to COVID-19Complicaciones renales secundarias a COVID-19Rozas-Olivera, Victor VladimiroCOVID-19sistema renina-angiotensina-aldosteronainjuria renal agudaCOVID-19renin-angiotensin-aldosterone systemacute kidney injuryPatients treated with inhibitors or blockers of the renin-angiotensin-aldosterone system (RAAS), showed no increased risk to develop COVID-19, nor an increased risk to developed a more critical stage of the disease. Patients with COVID-19, at the time of hospitalization showed a high proportion of the presence of proteinuria and hematuria. Reports from Europe and the United States showed that patients with COVID-19, whom required intensive care unit care, had an incidence of acute kidney injury (AKI) of 20% to 40%, and its onset showed a temporal relationship to the initiation of mechanical ventilation. Pathological findings showed that the principal cause of the renal injury was the development of acute tubular necrosis. The surge of patients with COVID-19 and AKI, demanded extraordinary efforts from health systems, to provide specialized medical personal and equipment for dialysis therapy.Los pacientes tratados con inhibidores o bloqueadores del sistema renina-angiotensina-aldosterona (SRAA) no muestran un riesgo incrementado para la infección con COVID-19 ni de desarrollar un estadio más crítico de la enfermedad. Al momento de ser hospitalizados, los pacientes con COVID-19, en una proporción elevada presentan proteinuria y hematuria. Reportes de Europa y los Estados Unidos muestran que los pacientes con COVID-19, que requieren de cuidados intensivos, presentan una incidencia de injuria renal aguda (IRA) en un porcentaje del 20% al 40%; el inicio de la IRA, tiene una relación temporal con el comienzo de la ventilación mecánica. Los hallazgos patológicos en estos pacientes indican la presencia de necrosis tubular aguda como causa principal de la injuria renal. Aproximadamente el 14% de pacientes con IRA, requiere de terapia de remplazo renal, y están asociados a tasas de mortalidad del 35% al 55%. Ante un incremento súbito de pacientes con COVID-19 e IRA, los sistemas de salud necesitaron de esfuerzos extraordinarios para poder proveer personal médico especializado y de equipos para terapia de diálisis.Fundación Instituto Hipólito Unanue2021-01-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/23510.33734/diagnostico.v59i3.235Diagnóstico; Vol. 59 No. 3 (2020); 125-132Diagnostico; Vol. 59 Núm. 3 (2020); 125-1321018-28882709-795110.33734/diagnostico.v59i3reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/235/239Derechos de autor 2021 Victor Vladimiro Rozas-Oliverainfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/2352021-06-04T17:54:48Z
dc.title.none.fl_str_mv Renal complications to COVID-19
Complicaciones renales secundarias a COVID-19
title Renal complications to COVID-19
spellingShingle Renal complications to COVID-19
Rozas-Olivera, Victor Vladimiro
COVID-19
sistema renina-angiotensina-aldosterona
injuria renal aguda
COVID-19
renin-angiotensin-aldosterone system
acute kidney injury
title_short Renal complications to COVID-19
title_full Renal complications to COVID-19
title_fullStr Renal complications to COVID-19
title_full_unstemmed Renal complications to COVID-19
title_sort Renal complications to COVID-19
dc.creator.none.fl_str_mv Rozas-Olivera, Victor Vladimiro
author Rozas-Olivera, Victor Vladimiro
author_facet Rozas-Olivera, Victor Vladimiro
author_role author
dc.subject.none.fl_str_mv COVID-19
sistema renina-angiotensina-aldosterona
injuria renal aguda
COVID-19
renin-angiotensin-aldosterone system
acute kidney injury
topic COVID-19
sistema renina-angiotensina-aldosterona
injuria renal aguda
COVID-19
renin-angiotensin-aldosterone system
acute kidney injury
description Patients treated with inhibitors or blockers of the renin-angiotensin-aldosterone system (RAAS), showed no increased risk to develop COVID-19, nor an increased risk to developed a more critical stage of the disease. Patients with COVID-19, at the time of hospitalization showed a high proportion of the presence of proteinuria and hematuria. Reports from Europe and the United States showed that patients with COVID-19, whom required intensive care unit care, had an incidence of acute kidney injury (AKI) of 20% to 40%, and its onset showed a temporal relationship to the initiation of mechanical ventilation. Pathological findings showed that the principal cause of the renal injury was the development of acute tubular necrosis. The surge of patients with COVID-19 and AKI, demanded extraordinary efforts from health systems, to provide specialized medical personal and equipment for dialysis therapy.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/235
10.33734/diagnostico.v59i3.235
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/235
identifier_str_mv 10.33734/diagnostico.v59i3.235
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/235/239
dc.rights.none.fl_str_mv Derechos de autor 2021 Victor Vladimiro Rozas-Olivera
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2021 Victor Vladimiro Rozas-Olivera
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 59 No. 3 (2020); 125-132
Diagnostico; Vol. 59 Núm. 3 (2020); 125-132
1018-2888
2709-7951
10.33734/diagnostico.v59i3
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1847158630613254144
score 13.065919
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).